Top 20 licensing deals show shrinking dollar amounts

Most biotech analysts have been concentrating heavily on the weakened flow of venture dollars into the industry. But if you look at the licensing side of the business, you'll also find some solid reasons for concern. For more, check out our list of the Top 20 biotech licensing deals this year. Report